|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Psoriasis Q4 2011
Medpredict, Nov 2011, Pages: 159
Psoriasis Thought Leader Panel #21 is a thought exercise conducted with six experts in the management of psoriasis/psoriatic arthritis in November 2011. The purpose of this exercise was to identify their “must have” branded and generic drugs for their real-world practice in the year 2016.
As with all of our syndicated reports, the identities of the Thought Leaders who participated have been censored. In this report we share each Panelist’s “Fantasy Formulary”, and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.
For this report the Panelists offered their insight into competitive dynamics of the following classes of therapeutics for psoriasis and/or psoriatic arthritis:
- IL-6, IL-12, IL-17, IL-20, IL-22, IL-23
- JAK1, JAK2, JAK3, TYK2
- Innate Immunity (IL-I, IFNa, TLR, Dendritic, T-Cell)
- Antimetabolites
- p38
- PDE-4
- protein kinase C
- S1P
- TNF
- Fumaric acid esters
- CTLA4
|
|
|
|
